Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma

被引：21

作者：

Bhatt, Vijaya Raj ^{[1
]}

Vose, Julie M. ^{[1
]}

机构：

[1] Univ Nebraska Med Ctr, Dept Internal Med, Div Hematol Oncol, Omaha, NE 68198 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2014年 / 28卷 / 06期

关键词：

Non-Hodgkin lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Peripheral T-cell lymphoma; Autologous hematopoietic stem cell transplantation; Allogeneic hematopoietic stem cell transplantation; HIGH-DOSE THERAPY; PROGRESSION-FREE SURVIVAL; INTERNATIONAL PROGNOSTIC INDEX; DETUDE DES LYMPHOMES; RITUXIMAB MAINTENANCE THERAPY; ADVANCED FOLLICULAR LYMPHOMA; BONE-MARROW-TRANSPLANTATION; LONG-TERM SURVIVAL; PHASE-II TRIAL; T-CELL;

D O I：

10.1016/j.hoc.2014.08.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Up-front rituximab-based chemotherapy has improved outcomes in non-Hodgkin lymphoma (NHL); refractory or relapsed NHL still accounts for approximately 18,000 deaths in the United States. Autologous hematopoietic stem cell transplantation (SCT) can improve survival in primary refractory or relapsed aggressive NHL and mantle cell lymphoma and in relapsed follicular or peripheral T-cell lymphoma. Autologous SCT as a consolidation therapy after first complete or partial remission in high-risk aggressive NHL, mantle cell lymphoma, and peripheral T-cell lymphoma may improve progression-free survival. Allogeneic SCT offers a lower relapse rate but a higher nonrelapse mortality resulting in overall survival similar to autologous SCT.

引用

页码：1073 / +

页数：24

共 116 条

[81] HIGH-DOSE THERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION AFTER FAILURE OF CONVENTIONAL CHEMOTHERAPY IN ADULTS WITH INTERMEDIATE-GRADE OR HIGH-GRADE NON-HODGKINS-LYMPHOMA [J].

PHILIP, T ;

ARMITAGE, JO ;

SPITZER, G ;

CHAUVIN, F ;

JAGANNATH, S ;

CAHN, JY ;

COLOMBAT, P ;

GOLDSTONE, AH ;

GORIN, NC ;

FLESH, M ;

LAPORTE, JP ;

MARANINCHI, D ;

PICO, J ;

BOSLY, A ;

ANDERSON, C ;

SCHOTS, R ;

BIRON, P ;

CABANILLAS, F ;

DICKE, K .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (24) :1493-1498

[82] AUTOLOGOUS BONE-MARROW TRANSPLANTATION AS COMPARED WITH SALVAGE CHEMOTHERAPY IN RELAPSES OF CHEMOTHERAPY-SENSITIVE NON-HODGKINS-LYMPHOMA [J].

PHILIP, T ;

GUGLIELMI, C ;

HAGENBEEK, A ;

SOMERS, R ;

VANDERLELIE, H ;

BRON, D ;

SONNEVELD, P ;

GISSELBRECHT, C ;

CAHN, JY ;

HAROUSSEAU, JL ;

COIFFIER, B ;

BIRON, P ;

MANDELLI, F ;

CHAUVIN, F .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (23) :1540-1545

[83] Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study [J].

Pott, Christiane ;

Hoster, Eva ;

Delfau-Larue, Marie-Helene ;

Beldjord, Kheira ;

Boettcher, Sebastian ;

Asnafi, Vahid ;

Plonquet, Anne ;

Siebert, Reiner ;

Callet-Bauchu, Evelyne ;

Andersen, Niels ;

van Dongen, Jacques J. M. ;

Klapper, Wolfram ;

Berger, Francoise ;

Ribrag, Vincent ;

van Hoof, Achiel L. ;

Trneny, Marek ;

Walewski, Jan ;

Dreger, Peter ;

Unterhalt, Michael ;

Hiddemann, Wolfgang ;

Kneba, Michael ;

Kluin-Nelemans, Hanneke C. ;

Hermine, Olivier ;

Macintyre, Elizabeth ;

Dreyling, Martin .

BLOOD, 2010, 115 (16) :3215-3223

[84]

Press OW, 2000, BLOOD, V96, P2934

[85] Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study [J].

Reimer, Peter ;

Ruediger, Thomas ;

Geissinger, Eva ;

Weissinger, Florian ;

Nerl, Christoph ;

Schmitz, Norbert ;

Engert, Andreas ;

Einsele, Hermann ;

Mueller-Hermelink, Hans Konrad ;

Wilhelm, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (01) :106-113

[86] The adjusted International Prognostic Index and β-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma [J].

Rodriguez, Jose ;

Conde, Eulogio ;

Gutierrez, Antonio ;

Lahuerta, Juan Jose ;

Arranz, Reyes ;

Sureda, Anna ;

Zuazu, Javier ;

Fernandez de Sevilla, Alberto ;

Bendandi, Maurizio ;

Solano, Carlos ;

Leon, Angel ;

Rosario Varela, Maria ;

Dolores Caballero, Maria .

HAEMATOLOGICA, 2007, 92 (08) :1067-1074

[87] Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients [J].

Roland, V. ;

Bodet-Milin, C. ;

Moreau, A. ;

Gastinne, T. ;

Mahe, B. ;

Dubruille, V. ;

Maisonneuve, H. ;

Juge-Morineau, N. ;

Moreau, P. ;

Jardel, H. ;

Planche, L. ;

Mohty, M. ;

Moreau, P. ;

Harousseau, J-L ;

Kraeber-Bodere, F. ;

Le Gouill, S. .

BONE MARROW TRANSPLANTATION, 2011, 46 (03) :393-399

[88] How I treat late effects in adults after allogeneic stem cell transplantation [J].

Savani, Bipin N. ;

Griffith, Michelle L. ;

Jagasia, Shubhada ;

Lee, Stephanie J. .

BLOOD, 2011, 117 (11) :3002-3009

[89] Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1) [J].

Schmitz, Norbert ;

Nickelsen, Maike ;

Ziepert, Marita ;

Haenel, Mathias ;

Borchmann, Peter ;

Schmidt, Christian ;

Viardot, Andreas ;

Bentz, Martin ;

Peter, Norma ;

Ehninger, Gerhard ;

Doelken, Gottfried ;

Ruebe, Christian ;

Truemper, Lorenz ;

Rosenwald, Andreas ;

Pfreundschuh, Michael ;

Loeffler, Markus ;

Glass, Bertram .

LANCET ONCOLOGY, 2012, 13 (12) :1250-1259

[90] High-dose, therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial [J].

Schouten, HC ;

Qian, W ;

Kvaloy, S ;

Porcellini, A ;

Hagberg, H ;

Johnsen, HE ;

Doorduijn, JK ;

Sydes, MR ;

Kvalheim, G .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3918-3927

← 3 4 5 6 7 8 9 10 11 12 →